首页> 外文OA文献 >Economic evaluation of lenalidomide (Revlimid®) for the treatment of mielodysplastic syndrome with 5q deletion at low/intermediate-1 risk

【2h】

Economic evaluation of lenalidomide (Revlimid®) for the treatment of mielodysplastic syndrome with 5q deletion at low/intermediate-1 risk

机译：来那度胺（Revlimid®）治疗低/中度1风险5q缺失的mielodysplastic综合征的经济学评价

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Christian Ramos; Efreen Montaño; Alfonso Reyes-López; Fabiola Lemus; Maria Pacheco; Gabriela Hernandez; Arely Lemus;
展开▼
作者单位

展开▼
年度 2017
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Lenalidomide is active in Japanese patients with symptomatic anemia in low- or intermediate-1 risk myelodysplastic syndromes with a deletion 5q abnormality. [J] . Harada H, Watanabe M, Suzuki K International journal of hematology . 2009,第3期

机译：来那度胺在患有低中或中度1风险性骨髓增生异常综合征且缺失5q异常的日本症状性贫血患者中活跃。
2. Lenalidomide is active in Japanese patients with symptomatic anemia in low- or intermediate-1 risk myelodysplastic syndromes with a deletion 5q abnormality [J] . Hironori Harada, Mitsumasa Watanabe, Kenshi Suzuki, International Journal of Hematology . 2009,第3期

机译：来那度胺活跃于日本中低度或中度1风险性骨髓增生异常综合征伴有5q缺失缺失的症状性贫血患者
3. Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS) [J] . Azra Raza, Naomi Galili, Deborah Mulford, Journal of Hematology and Oncology . 2012,第5期

机译：盐酸依泽替司他联合来那度胺在非缺失（5q）低至中度-1风险性增生异常综合症（MDS）患者中的1期剂量范围研究
4. Superior Mesenteric Artery Syndrome Following Scoliosis Surgery: Its Risk Indicators and Treatment Strategy [C] . Zezhang ZHU, Yong QIU, Bin WANG, International Research Society of Spinal Deformities . 2008

机译：脊柱侧凸手术后卓越的肠系膜动脉综合征：其风险指标和治疗策略
5. Assessment of parent/caregivers' level of guilt, worry, and uncertainty related to their child's increased risk of psychiatric disorders associated with 22q11 deletion syndrome. [D] . Hilber, Renee Elizabeth. 2009

机译：评估父母/监护人的内感，忧虑和不确定性，与他们的孩子与22q11缺失综合征相关的精神疾病风险增加有关。
6. Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS) [O] . Azra Raza, Naomi Galili, Deborah Mulford, 2012

机译：盐酸依泽替司他联合来那度胺用于非缺失（5q）低至中度-1危险性增生异常综合征（MDS）患者的1期剂量范围研究
7. Lenalidomide (Revlimid®) for the treatment of low /intermediate-1 risk myelodysplastic syndrome with chromosome 5q deletion [O] . Nachtnebel A., Maran P.R., Alberti C., 2012

机译：来那度胺（Revlimid®）用于治疗5q号染色体缺失的低危/中危1型骨髓增生异常综合症

Economic evaluation of lenalidomide (Revlimid®) for the treatment of mielodysplastic syndrome with 5q deletion at low/intermediate-1 risk

著录项

引文网络

相似文献

相关主题

期刊订阅